Title:
TRICYCLIC HPK1 INHIBITOR AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/188823
Kind Code:
A1
Abstract:
The present invention relates to the technical field of medicines, and in particular to a tricyclic HPK1 inhibitor compound or a pharmaceutically acceptable salt or stereoisomer thereof, a pharmaceutical composition and a preparation containing said compound or the pharmaceutically acceptable salt or stereoisomer thereof, a method for preparing said compound or the pharmaceutically acceptable salt or stereoisomer thereof, and a use of said compound or the pharmaceutically acceptable salt or stereoisomer thereof.
Inventors:
LIU BIN (CN)
Application Number:
PCT/CN2022/080065
Publication Date:
September 15, 2022
Filing Date:
March 10, 2022
Export Citation:
Assignee:
SHANDONG XUANZHU PHARMA CO LTD (CN)
International Classes:
C07D519/00; A61K31/437; A61K31/55; A61K31/551; A61P35/00; A61P35/02; C07D495/04
Domestic Patent References:
| WO2016205942A1 | 2016-12-29 |
Foreign References:
| CN109721620A | 2019-05-07 |
Other References:
SONG, PINRAO ET AL.: "Design, Synthesis and Biological Evaluation of Thienopyridinones As Chk1 Inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 22, no. 17, 28 June 2014 (2014-06-28), pages 4882 - 4892, XP055340445, DOI: 10.1016/j.bmc.2014.06.044
Download PDF: